Autres langues Clene Inc.

Actions

CLNN

US1856342019

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 23/09/2026			Varia. 5j.	Varia. 1 janv.
4,290 ^USD	-2,05%		+11,14%	-26,92%

15/09	Les plus fortes hausses de la mi-séance	MT
14/08	Clene Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Autres langues

22/09	Clene to Present at Upcoming Investor Conferences
21/09	Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA
15/09	Top Midday Gainers
15/09	Clene Announces $4 Million Registered Direct Offering
03/09	Clene to Present at Upcoming September Investor Conferences
17/08	Clene to Present at the Emerging Growth Conference
14/08	Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights
14/08	Clene Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
10/08	Clene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval
10/08	Clene Inc. Announces Biomarker Analyses to Be Included in NDA Submission Supporting ALS Accelerated Approval
29/07	Clene to Present at The Canaccord 46th Annual Growth Conference
29/06	Clene Inc.(NasdaqCM:CLNN) added to Russell Microcap Value Benchmark Index
29/06	Clene Inc.(NasdaqCM:CLNN) added to Russell Microcap Index
29/06	Clene Inc.(NasdaqCM:CLNN) added to Russell 3000E Value Benchmark
29/06	Clene Inc.(NasdaqCM:CLNN) added to Russell 3000E Index
22/06	Top Premarket Decliners
14/05	Clene Inc - Enters second amendment to senior secured convertible notes - SEC filing
14/05	Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights
14/05	Clene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
14/05	Clene Insider Sold Shares Worth $604,130, According to a Recent SEC Filing
05/05	Clene Inc - announces common stock offering - SEC filing
05/05	Clene announces $7 million underwritten offering of common stock
05/05	Clene Announces $7 Million Underwritten Offering of Common Stock
05/05	Clene to Present at Upcoming May Conferences
04/05	After successful FDA meeting, Clene filing accelerated approval NDA for ALS